Management of Henoch-Schönlein Purpura
For most patients with Henoch-Schönlein purpura, supportive care alone is sufficient, as the disease spontaneously resolves in 94% of children and 89% of adults; however, corticosteroids should be used for severe abdominal pain and early aggressive immunosuppressive therapy is indicated for progressive renal disease. 1
Initial Management: Supportive Care
The foundation of HSP management is supportive treatment, given the high spontaneous resolution rate. This includes:
- Analgesics and NSAIDs for joint pain, inflammation, and painful cutaneous edema 2
- Monitoring for complications, particularly renal involvement
- No treatment may be appropriate for mild cases with minimal proteinuria 3
Corticosteroid Indications
For Abdominal and Joint Symptoms
Oral prednisone at 1-2 mg/kg daily for two weeks is the standard approach for:
- Severe abdominal pain
- Significant joint symptoms 1
The evidence supporting this is compelling: corticosteroids significantly reduce the mean time to resolution of abdominal pain and increase the odds of resolution within 24 hours 4. For articular involvement specifically, corticosteroids achieve rapid remission when NSAIDs or acetaminophen fail 5.
For Renal Protection
Early corticosteroid treatment significantly reduces the odds of developing persistent renal disease 4. This is a critical finding that shifts the risk-benefit calculation toward early intervention when renal involvement is present or anticipated.
Renal Disease Management Algorithm
Mild Renal Involvement (Hematuria ± Mild Proteinuria)
For patients with isolated hematuria or mild proteinuria:
- Consider observation alone or ACE inhibitors/ARBs as first-line 3
- Over 90% of patients with mild disease achieve remission with renin-angiotensin-aldosterone system inhibitors alone or no treatment 3
Moderate to Severe Renal Involvement
For progressive HSP nephritis with significant proteinuria or declining renal function, aggressive immunosuppressive therapy is warranted 2, 1:
- Mycophenolate mofetil combined with conventional therapy (MMF+CT) offers the best balance between efficacy and safety, particularly for controlling proteinuria and hypoalbuminemia 6
- Tacrolimus combined with conventional therapy (TAC+CT) is most suitable for patients with impaired renal function (best performance in improving serum creatinine) 6
- Tripterygium wilfordii polyglycoside combined with conventional therapy is most effective for rapid symptom control, shortening time to resolution of hematuria and proteinuria 6
Alternative agents when standard therapy fails include rituximab, methotrexate, cyclophosphamide, or azathioprine 5.
Important Caveats and Pitfalls
Avoid premature escalation to aggressive immunosuppression in mild cases. The 2022 Japanese study demonstrates that several patients achieve remission without treatment or with ACE inhibitors alone, emphasizing the need for careful treatment selection 3.
Monitor for renal involvement closely: 40-50% of patients develop renal disease, and this determines long-term prognosis. End-stage renal disease occurs in 1-5% of patients 1.
Consider infection screening before immunosuppression: Screen for tuberculosis, hepatitis B/C, HIV, and consider Strongyloides in endemic areas. Prophylactic trimethoprim-sulfamethoxazole should be considered with high-dose prednisone or other immunosuppressive agents 7.
Adults require more vigilant monitoring as they are more likely to experience complications than children 1.
Treatment Intensity Based on Presentation
The severity of presenting symptoms and type of glomerulonephritis should dictate induction therapy intensity, with GFR taken into account for safe dosing 7. The goal is to avert immediate morbidity while preventing disease progression and minimizing immunosuppression-related adverse effects 7.